Week of July 18, 2023 | Vol. 12, Issue 28

UPCOMING EVENTS

Events Hosted or Attended by Bourne Partners

INDUSTRY M&A ACTIVITY

Recent Transactions, Trading Comps, Market Reports, M&A Pipeline

Recent Transactions

An Overview of Transactions Within Market Sub-segments

Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.

Trading Comps

A Breakdown of Relevant Trading Multiples

This is a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

Market Reports

Insight Into Healthcare Related Industries

Pharma Services Sector Snapshot 1H 2022

August 2022

Pharma Sector Snapshot 1H 2022

August 2022

Market Insight Capital Markets Update

October 2022

M&A Pipeline

Representative Current Retained Sell-Side and Partnering Opportunities

Project Beach

Pharma Services | Sell-Side

Acquisition opportunity of Clinical Trial Services Provider

Project Elevate

Pharma Services | Capital Raise

Investment opportunity in Digital Health patient adherence platform

Project Ester

Consumer Health | Strategic Partnering 

Partnering opportunity for launch and commercialization of novel OTC dry eye product

Project Harold

Pharma Services | Sell-Side

Acquisition opportunity of U.S. based Sterile CDMO

Project Panther

Pharma Services | Sell-Side

Acquisition opportunity of OTC and personal care CDMO

Project Pine

Pharma Services | Capital Raise

Investment opportunity in sterile injectable Pharmaceutical Manufacturer 

Project Trident

Pharma | Buy-Side

Seeking generic liquids or established brands across all formats sold through the hospital / institutional channel

Featured Headlines

A Sampling of Industry Headlines

How Big Pharma implements analytics in continuous manufacturing

Pharma Technology Focus

Astellas eyes rare ophthalmology, licensing 4DMT's viral vector for gene therapy for up to $962M

Endpoints News- Jul 10, 2023

BeiGene Ups ADC Investment with $1.3B DualityBio Licensing Deal

BioSpace - Jul 10, 2023

WuXi Biologics seeks spinout, HK listing of bioconjugates-focused joint venture

Endpoints News - Jul 10, 2023

Samsung Biologics, after expanding Pfizer collab, inks Novartis production deal worth $391M

Fierce Pharma - Jul 10, 2023

Kindeva Drug Delivery, Chiesi Group, and H&T Presspart Announce Strategic Partnership for Dose Counter Technology Production

Kindeva Drug Delivery - Jul 11, 2023

Exclusive: Pfizer to invest $25M into tiny UK biotech with epigenetics approach to cancer

Endpoints News - Jul 11, 2023

Avrobio halts gene therapy research and considers a sale

Biopharma Dive - Jul 12, 2023

Velocity teams with Privia Health for new embedded clinical research sites

Fierce Biotech - Jul 12, 2023

Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products

FDA - Jul 13, 2023

Novartis adds more partners to Beacon of Hope initiative for HBCUs and clinical trial diversity

Fierce Biotech - Jul 13, 2023

Innovative drug formulations make medicines more patient-friendly: Aenova and Galvita enter strategic partnership

Aenova - Jul 13, 2023

FDA Approves First Nonprescription Daily Oral Contraceptive

FDA - Jul 13, 2023

AI in healthcare: PE using tech from front to back office

PE Hub- Jul 17, 2023

TANNER NEWS

Enabling Access Continuity of Medical Treatments for Patients

There are different instances where patients may experience interruptions in treatment access, entirely lose access they once had, or completely lack access to a commercialized medicine that just isn’t available where they live. The common denominator being that all factors are almost always beyond the patient’s control. Read more.